SCNI

JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placement of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 Warrants to purchase up to 3,687,501 ADSs (the "Private Placement").

JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 warrants to purchase up to 3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisable immediately with a term of five years, at a combined purchase price of $1.20 per ADS and accompanying warrants (or $1.1999 per pre-funded warrant and accompanying warrants).

Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027 Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late 2027 through the first half of 2028, excluding additional scale-up, qualification and initial manufacturing activities not yet priced JERUSALEM, Oct. 13, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd.

Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.